Biovie Inc receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Consumer Goods, Healthcare and Financials sectors led shares higher while losses in the Oil & Gas,...
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Industrials, Basic Materials and Technology sectors led shares lower. At the close in NYSE,...
BioVie Inc. is a clinical-stage company. The Company is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
| Average | 9.75 (+96.57% Upside) |
| High | 12.00 |
| Low | 7.00 |
| Price | 4.96 |
| No. of Analysts | 4 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 143.00 | 145.55 | 142.85 | -2.93 | -2.01% | 62.93M | NASDAQ | |||
| 123.19 | 124.96 | 120.48 | +1.81 | +1.49% | 791.27K | NYSE | |||
| 4.91 | 7.27 | 4.80 | +0.96 | +24.30% | 112.89M | NYSE | |||
| 8.36 | 8.52 | 8.31 | -0.04 | -0.48% | 825.70K | NYSE | |||
| 78.93 | 79.74 | 78.93 | -0.68 | -0.85% | 2.39M | NYSE | |||
| 6.68 | 7.01 | 6.37 | +0.74 | +12.46% | 163.46M | NASDAQ | |||
| 175.96 | 178.53 | 175.54 | +0.28 | +0.16% | 2.07M | NASDAQ | |||
| 111.52 | 113.57 | 105.78 | +6.08 | +5.77% | 1.34M | NASDAQ | |||
| 113.56 | 115.49 | 113.15 | -2.05 | -1.77% | 18.50M | NYSE | |||
| 11.28 | 11.49 | 11.23 | -0.01 | -0.09% | 21.72M | NYSE | |||
| 13.00 | 13.00 | 13.00 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 0.82 | 0.86 | 0.82 | -0.0371 | -4.33% | 89.03K | NASDAQ | |||
| 41.05 | 41.26 | 40.70 | +0.41 | +1.01% | 21.87M | NYSE | |||
| 25.00 | 26.00 | 24.33 | -1.98 | -7.34% | 7.89K | NASDAQ | |||
| 36.68 | 37.71 | 36.63 | -1.03 | -2.73% | 1.18M | NYSE |